FDA Determines Regulatory Review Period for SEGLUROMET Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of SEGLUROMET, a human drug product, following submissions to the US Patent and Trademark Office (USPTO).